BiomX To Present at Plenary Session of the AASLD Liver Conference

NESS ZIONA, Israel--()--BiomX Inc. (NYSE: PHGE), a microbiome company developing both natural and engineered phage therapies, today announced that BiomX’s Chief Medical Officer, Sailaja Puttagunta, M.D., will present pre-clinical data from the company’s liver program at the plenary session of the American Association for The Study of Liver Diseases (AASLD) taking place in Boston, Massachusetts from November 8 - November 12, 2019.

Details of the presentation are listed below:

The Liver Meeting 2019

Title:

Use of a bacteriophage cocktail for eradication of klebsiella pneumonia in primary sclerosing cholangitis

Publication Number:

0026

Session Title:

Presidential Plenary: Translational

Session Date and Time:

Tuesday, November 12, 2019, 9:00 am

Presentation Time:

9:15 am

Presentation Type:

Oral, parallel session

Location:

Auditorium, Hynes Convention Center

About BiomX

BiomX is a clinical stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

www.biomx.com

Safe Harbor Language

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. You should review additional disclosures we make in our filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov.

Contacts

MacDougall
Shai Biran, Ph.D.
Direct: +1 781 235 3060
sbiran@macbiocom.com

Release Summary

BiomX’s CMO, Sailaja Puttagunta, M.D., will present pre-clinical data from the company’s liver program at the plenary session of AASLD

#Hashtags

Contacts

MacDougall
Shai Biran, Ph.D.
Direct: +1 781 235 3060
sbiran@macbiocom.com